首页> 美国卫生研究院文献>Filaria Journal >Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
【2h】

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol

机译:葡甲胺锑酸盐加别嘌呤醇与米替福辛加别嘌呤醇治疗的利什曼病狗的长期随访

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundVisceral leishmaniosis is a potentially life-threatening illness caused by a protozoan parasite of the genus Leishmania. It is found mainly in areas where both the parasite and its vector are endemic and is one of the most challenging infectious diseases in the world to control. HIV infected patients are vulnerable to Leishmania infections, and the main reservoir hosts of Leishmania infantum parasites are domestic dogs. Here, we evaluated the long-term efficacy of treatment with meglumine antimoniate plus allopurinol (G1) compared to miltefosine plus allopurinol (G2) in dogs naturally infected L. infantum.
机译:背景内脏利什曼病是由利什曼原虫属的原生动物寄生虫引起的潜在威胁生命的疾病。它主要在寄生虫及其媒介都是地方性的地区发现,是世界上最难控制的传染病之一。受HIV感染的患者很容易感染利什曼原虫,婴儿利什曼原虫寄生虫的主要宿主是家犬。在这里,我们评估了米格鲁宁锑酸加别嘌呤醇(G1)与米替福辛加别嘌呤醇(G2)在自然感染婴儿乳杆菌中的狗的长期疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号